David King (former LabCorp CEO) joining the board. That's a very deliberate pick. He ran LabCorp from 2007-2019, which means he knows the reference lab world inside and out, including being on the buy side of sequencing instruments and consumables. Given Illumina's push toward clinical (now ~60% of revenue), having someone who understands the payer/lab/health system intersection is a clear signal about where they think growth comes from. He also chaired PathGroup and LGC Limited and sits on Novant Health's board. This is a clinical/commercial operator, not a technology visionary.
Three directors leaving at once. Arnold, Epstein, and Guthart are all out. That's the Science and Technology Committee chair (Arnold) and two long-tenured members. Losing Frances Arnold (Nobel laureate, directed evolution) from the S&T Committee is notable. The board is getting younger and more commercially oriented. Only King is coming in as a replacement, so the board shrinks from 11 to 9.
Meister/Corvex position is massive. Keith Meister is a hedge fund manager who founded Corvex Management, an investment firm known for taking large stakes in public companies and then pushing for changes to increase the stock price. Before starting Corvex, he was Carl Icahn's right-hand man, serving as CEO of Icahn Enterprises. Icahn is one of the most famous activist investors in history, someone who buys big positions in companies he thinks are undervalued or mismanaged and then pressures the board to make changes. Meister learned that playbook firsthand.
Corvex now holds 4.2 million Illumina shares (2.8% of the company). On top of that, they have financial contracts (equity swaps) with a bank that give them economic exposure to another ~369K shares at a locked-in price of $102.82 per share. Those contracts can be converted into actual share ownership at Corvex's option, meaning Meister can increase his voting stake whenever he wants.
Rather than waging a public fight, Meister took a board seat in March 2025, which is the more cooperative version of activism: get inside the boardroom and push for changes from within. He sits on the Nominating/Corporate Governance Committee, which controls who gets nominated to the board and oversees CEO succession planning. That's a power position.
He also sits on the GeneDx board, a publicly traded genomics company focused on rare disease diagnostics that uses Illumina sequencers, which creates an interesting web of relationships across the sequencing ecosystem.
The overall read: Corvex has made a big bet that Illumina's stock (down ~64% from 2021 levels) is undervalued, and Meister is now inside the boardroom with real leverage over strategy, capital allocation, and leadership decisions. The board shrinking from 11 to 9 seats concentrates his influence further.
CEO comp took a haircut. Thaysen's total compensation dropped from $14.8M to $11M. They froze all executive salaries and cut stock-based awards as a "one-time" response to the China/NIH/tariff headwinds. But his annual cash bonus target went from 125% to 150% of base salary, and the maximum payout on his performance-based stock awards (shares that only vest if the company hits multi-year financial goals) jumped from 200% to 250% of target. So the structure got more aggressive even as the headline dollar amount came down. They've already restored everything for 2026.
Annual bonus payout was 77% of target. The company's variable cash bonus plan (paid annually based on hitting preset financial goals) missed on both metrics: revenue ($4,356M actual vs $4,410M target) and adjusted operating income ($1,298M vs $1,367M target). Notably, they excluded China results entirely from the bonus calculation, treating China as "achieved at budget." That's a pretty generous accommodation given the UEL situation.
Everett Cunningham (Chief Commercial Officer) resigned January 16, 2026 for "a CEO opportunity at a life science tools company." He forfeited all unvested stock awards, was ineligible for his annual bonus, and had to repay his $500K sign-on bonus. Less than two years in the seat. That's the commercial leadership role turning over at a critical time.
Say-on-pay got 91% support in 2025. (Say-on-pay is the annual non-binding shareholder vote on whether they approve of how executives are being compensated. 91% approval means no shareholder revolt brewing on comp.)
Stock performance story is brutal. The proxy's pay-versus-performance table shows that $100 invested in Illumina stock on January 3, 2021 would have been worth just $36.47 at the end of fiscal 2025, a roughly 64% loss. Over the same period, $100 invested in the Nasdaq Biotech Index would have grown to $122.07, a 22% gain. The 2023 performance stock awards (shares that only pay out based on how Illumina's stock return compares to peers over three years) landed at the 37th percentile, meaning Illumina underperformed nearly two-thirds of comparable biotech companies, resulting in executives receiving only 74% of their target share count.